The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
Thomas O. Bergmeijer(St. Antonius Ziekenhuis), Paul A. Gurbel(Sinai Hospital), Brian A. Moser(Eli Lilly (United States)), Dominick J. Angiolillo(University of Florida), Tomas Lindahl(Linköping University), Scott S. Sundseth, David Erlinge(Lund University), Kenneth J. Winters(Eli Lilly (United States)), Patricia Brown(Eli Lilly (United States)), Peter J Svensson(Malmö University), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Suman Duvvuru(Eli Lilly (United States)), Joseph R. Walker(Daiichi Sankyo (United States)), David S. Small(Eli Lilly (United States)), Jurriën M. ten Berg(St. Antonius Ziekenhuis), Stefan James(Uppsala University Hospital), Udaya S. Tantry(Sinai Hospital)
Cited by 32
Related Papers
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k
The Obesity-Associated <i>FTO</i> Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase
|Science|2007|1.5k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825